Paper Details

  1. Home
  2. Paper Details

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.

Author: , BlakeLesley M, KaganEthel, OttBrian R, ResnickMalca

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Memantine, a medication that blocks a specific type of brain receptor (NMDA), has been found safe and effective in improving thinking, functioning, behavior, and overall well-being in people with moderate to severe Alzheimer's disease (AD) for 3-6 months. It is approved for use in the US and Europe, and is currently being studied for patients with mild to moderate AD.
Paper Details　
Original Abstract of the Article :
Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be safe and to have beneficial effects on cognition, function, behavior, and global patient status in patients with Alzheimer's disease (AD) in studies lasting 3-6 months. It is approved in the U.S. and Europe for the t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00415-006-0374-x

データ提供：米国国立医学図書館（NLM）

Memantine for Mild to Moderate Alzheimer's Disease: A Long-Term Safety and Tolerability Study

Alzheimer's disease (AD), a debilitating neurodegenerative disorder, presents a significant challenge in the vast desert of neurological research. This study examines the long-term safety and tolerability of memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, in patients with mild to moderate AD. The authors, like skilled navigators venturing into uncharted territories, investigate the long-term implications of this drug for AD management.

Exploring the Long-Term Implications of Memantine

The study reveals that memantine has demonstrated safety and potential benefits for cognition, function, behavior, and global patient status in patients with AD in shorter-term studies. This extended study provides valuable insights into the long-term effects of memantine, like a well-traveled desert route, offering reassurance about its safety and potential effectiveness.

Navigating the Challenges of Alzheimer's Disease

This study is a step forward in understanding the long-term safety and tolerability of memantine for AD. It provides valuable information for healthcare professionals and patients, highlighting the need for further research into effective treatments for this debilitating disease. It is like a guidepost in the vast desert of AD research, pointing the way toward better therapies for patients and their families.

Dr. Camel's Conclusion

This study emphasizes the importance of long-term safety and tolerability studies for new medications. Memantine, like a trusty camel carrying valuable supplies, has shown promising results in the fight against Alzheimer's disease. This study serves as a reminder that we must continue to explore the vast desert of neurodegenerative research, seeking innovative solutions to improve the lives of patients with Alzheimer's disease.

Date :
  1. Date Completed 2007-07-06
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

17345042

DOI: Digital Object Identifier

10.1007/s00415-006-0374-x

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.